Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (62)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (235)
  2. Center for Hematologic Malignancies (235)
  3. Department of Medicine (235)
  4. Hematologic Malignancies, Division of (235)
  5. Lymphoma (47)
  6. GME, Medicine (32)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (3)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (235)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Chong, E. A.; Svoboda, J.; Nasta, S. D.; Landsburg, D. J.; Winchell, N.; Napier, E.; Mato, A. R.; Melenhorst, J. J.; Ruella, M.; Lacey, S. F.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetic, and pharmacodynamic results from a phase 1b/2 dose-escalation and cohort-expansion study of the noncovalent, reversible Bruton's tyrosine kinase inhibitor (BTKi), vecabrutinib, in B-lymphoid malignancies
    Meeting Abstract

    Allan, J. N.; Wierda, W. G.; Patel, K.; O'Brien, S. M.; Mato, A. R.; Davids, M. S.; Furman, R. R.; Pagel, J. M.; Fox, J. A.; Ward, R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Lamanna, N.; Flinn, I.; Barrientos, J. C.; Kambhampati, S.; Cheson, B. D.; Barr, P. M.; Pagel, J. M.; Reeves, J. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world
    Meeting Abstract

    Nabhan, C.; Klink, A.; Samp, J.; Pauff, J. M.; Nielsen, J.; Meissner, B.; Keim, H.; Kennard, K.; Mato, A. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A US-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts)
    Meeting Abstract

    Koffman, B.; Dennison, B.; Kennard, K.; Byrd, J. C.; Pagel, J. M.; Davids, M. S.; Nabhan, C.; Kay, N. E.; Siddiqi, T.; Brander, D. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib
    Meeting Abstract

    Byrd, J. C.; Wierda, W. G.; Davids, M. S.; Choi, M. Y.; Furman, R. R.; Mato, A. R.; Zhou, L.; Verdugo, M. E.; Potluri, J.; Coutre, S.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL
    Meeting Abstract

    Davids, M. S.; Seymour, J. F.; Roberts, A. W.; Eichhorst, B.; Kipps, T. J.; Mato, A. R.; Stilgenbauer, S.; Mobasher, M.; Desai, M. B.; Potluri, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor – T-cell therapy in B-cell non-Hodgkin lymphomas
    Journal Article

    Shah, N. N.; Nagle, S. J.; Torigian, D. A.; Farwell, M. D.; Hwang, W. T.; Frey, N.; Nasta, S. D.; Landsburg, D.; Mato, A.; June, C. H.; more...
    Cytotherapy (2018)

    Fulltext@MSK | Save
  • Approaches to chronic lymphocytic leukemia therapy in the era of new agents: The conundrum of many options
    Journal Article

    Jain, N.; Thompson, P.; Ferrajoli, A.; Nabhan, C.; Mato, A. R.; O'Brien, S.
    American Society of Clinical Oncology Educational Book (2018)

    Fulltext@MSK | Save
  • Evidence for and against green tea and turmeric in the management of chronic lymphocytic leukemia
    Journal Article

    Bange, E.; Timlin, C.; Kabel, C.; Svoboda, J.; Roeker, L.; Mato, A. R.
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save